Gerdi Tuli1,2, Raffaele Buganza3,4, Daniele Tessaris3,4, Silvia Einaudi3,4, Patrizia Matarazzo3,4, Luisa de Sanctis3,4. 1. Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, City of Health and Science University Hospital of Turin, Turin, Italy. gtuli@unito.it. 2. Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy. gtuli@unito.it. 3. Department of Pediatric Endocrinology, Regina Margherita Children's Hospital, City of Health and Science University Hospital of Turin, Turin, Italy. 4. Department of Public Health and Pediatric Sciences, University of Turin, Turin, Italy.
Abstract
BACKGROUND: Hypoparathyroidism is characterized by the absence or inadequately low circulating concentrations of the parathyroid hormone, resulting in hypocalcemia, hyperphosphatemia, and elevated fractional excretion of calcium in the urine. The use of activated vitamin D analogs and calcium supplements represent conventional therapy. Subcutaneous recombinant human parathormone [rhPTH(1-34)] has been proposed as a substitutive treatment, even to avoid side effects of vitamin D and calcium. OBJECTIVE: To assess the long-term safety and efficacy of rhPTH(1-34) in a pediatric cohort of patients with genetic hypoparathyroidism. METHODS: The study is a 9.2-year self-controlled study of six pediatric patients (four males and two females, aged 9.4 ± 5.2) with DiGeorge, hypoparathyroidism-deafness-renal dysplasia (HDR) or autoimmune-candidiasis-polyendocrinopathy-ectodermal-dysplasia (APECED) syndrome, associated with autoimmune intestinal malabsorption in a patient. The presence of clinical signs of hypocalcemia and biochemical parameters, such as calcium, phosphate, alkaline phosphatase in the blood and calcium-creatinine ratio in urine, were compared during conventional treatment and rhPTH(1-34) (teriparatide, 12.5 μg twice daily). RESULTS: The rhPTH(1-34) treatment allowed a reduction, although not always a complete suspension, of calcium supplementation and a slight reduction of calcitriol therapy. The number of tetanic episodes was reduced in four patients during the rhPTH(1-34) treatment. Mean blood calcium, alkaline phosphatase, and phosphate did not significantly change, while a significant reduction of the urinary calcium-to-creatinine ratio (0.55 ± 0.32 vs 0.16 ± 0.09, p = 0.03) was obtained. Renal ultrasound examination showed a worsening in three patients, while it did not change in the remaining three subjects during the follow-up. CONCLUSIONS: In children with syndromic hypoparathyroidism presented here, replacement therapy with rhPTH(1-34) allowed to maintain adequate levels of the calcium and phosphate in the blood, normalize urinary calcium excretion, and reduce tetanic episodes. In patients with low compliance to conventional therapy or intestinal malabsorption, the use of rhPTH(1-34) could be considered, also to reduce the side effects of treatment with vitamin D and calcium.
BACKGROUND:Hypoparathyroidism is characterized by the absence or inadequately low circulating concentrations of the parathyroid hormone, resulting in hypocalcemia, hyperphosphatemia, and elevated fractional excretion of calcium in the urine. The use of activated vitamin D analogs and calcium supplements represent conventional therapy. Subcutaneous recombinant human parathormone [rhPTH(1-34)] has been proposed as a substitutive treatment, even to avoid side effects of vitamin D and calcium. OBJECTIVE: To assess the long-term safety and efficacy of rhPTH(1-34) in a pediatric cohort of patients with genetic hypoparathyroidism. METHODS: The study is a 9.2-year self-controlled study of six pediatric patients (four males and two females, aged 9.4 ± 5.2) with DiGeorge, hypoparathyroidism-deafness-renal dysplasia (HDR) or autoimmune-candidiasis-polyendocrinopathy-ectodermal-dysplasia (APECED) syndrome, associated with autoimmune intestinal malabsorption in a patient. The presence of clinical signs of hypocalcemia and biochemical parameters, such as calcium, phosphate, alkaline phosphatase in the blood and calcium-creatinine ratio in urine, were compared during conventional treatment and rhPTH(1-34) (teriparatide, 12.5 μg twice daily). RESULTS: The rhPTH(1-34) treatment allowed a reduction, although not always a complete suspension, of calcium supplementation and a slight reduction of calcitriol therapy. The number of tetanic episodes was reduced in four patients during the rhPTH(1-34) treatment. Mean blood calcium, alkaline phosphatase, and phosphate did not significantly change, while a significant reduction of the urinary calcium-to-creatinine ratio (0.55 ± 0.32 vs 0.16 ± 0.09, p = 0.03) was obtained. Renal ultrasound examination showed a worsening in three patients, while it did not change in the remaining three subjects during the follow-up. CONCLUSIONS: In children with syndromic hypoparathyroidism presented here, replacement therapy with rhPTH(1-34) allowed to maintain adequate levels of the calcium and phosphate in the blood, normalize urinary calcium excretion, and reduce tetanic episodes. In patients with low compliance to conventional therapy or intestinal malabsorption, the use of rhPTH(1-34) could be considered, also to reduce the side effects of treatment with vitamin D and calcium.
Authors: Rachel I Gafni; Lori C Guthrie; Marilyn H Kelly; Beth A Brillante; C Michele Christie; James C Reynolds; Nancy A Yovetich; Robert James; Michael T Collins Journal: J Bone Miner Res Date: 2015-08-03 Impact factor: 6.741
Authors: David L Kendler; Fernando Marin; Cristiano A F Zerbini; Luis A Russo; Susan L Greenspan; Vit Zikan; Alicia Bagur; Jorge Malouf-Sierra; Péter Lakatos; Astrid Fahrleitner-Pammer; Eric Lespessailles; Salvatore Minisola; Jean Jacques Body; Piet Geusens; Rüdiger Möricke; Pedro López-Romero Journal: Lancet Date: 2017-11-09 Impact factor: 79.321
Authors: Bente L Langdahl; Stuart Silverman; Saeko Fujiwara; Ken Saag; Nicola Napoli; Satoshi Soen; Hiroyuki Enomoto; Thomas E Melby; Damon P Disch; Fernando Marin; John H Krege Journal: Bone Date: 2018-07-18 Impact factor: 4.398
Authors: John L Vahle; Gerald G Long; George Sandusky; Michael Westmore; Yanfei Linda Ma; Masahiko Sato Journal: Toxicol Pathol Date: 2004 Jul-Aug Impact factor: 1.902
Authors: Maria Luisa Brandi; John P Bilezikian; Dolores Shoback; Roger Bouillon; Bart L Clarke; Rajesh V Thakker; Aliya A Khan; John T Potts Journal: J Clin Endocrinol Metab Date: 2016-03-04 Impact factor: 5.958